The nystatin dose for oral candidiasis in the BNF has historically reflected the posology recommendations in the Nystan® Summary of Product Characteristics (SPC). Following discussions with the MHRA the dose has been updated (live in digital versions of the BNF from March 2017) and now reflects current posology recommendations for generic nystatin products.
The BNF chapter numbering structure (sometimes referred to as the hierarchy) was changed in BNF70 in order to facilitate the development of digital products and the print restructuring of content.
We are aware that NHS organisations, especially hospitals, utilise the BNF’s chapter structure and have further developed it for a range of important uses which could be impacted by these changes, including, in particular, collecting and reporting data on medicines and other prescribable products. As well as local systems, this also affects NHS Business Services Authority’s prescriptions information systems and reports, the dm+d supplementary release file, and the publications and data releases by the Health and Social Care Information Centre.
A steering group with representation from the BNF Publisher, DH, HSCIC, NHSBSA, NICE, Devolved Administrations, All England Chief Pharmacists Group and the Pharmaceutical Advisors Group has been established meets quarterly. The group’s focus is on the development of an NHS owned information standard, which will eventually replace the legacy BNF chapter structure. Use of the standard will be mandated throughout the NHS to ensure consistency across all systems, although please note that this is a long term objective. The group will also focus on developing a strategy which will support the requirements of users throughout the NHS to make a smooth transition with minimal disruption. We will be consulting widely with users to help with this work.
We would like to reassure you that the BNF Publisher will continue to support the chapter structure featured in previous editions of the BNF through ‘BNF Legacy’, which is available on the www.medicinescomplete.com platform whilst solutions are implemented.
The February 2017 eNewsletter contains the latest guidance and content updates to the BNF and BNFC. This month includes 3 new monographs that have been added to the BNF.
Previous eNewsletters can be found below:
Have you ever wondered what processes go into the making of the BNF? Follow the journey of a single piece of content on its way to publication with our infographic.
The September 2016 issue of the BNF eNewsletter contains the latest guidance and content updates to the BNF and BNFC. This month also sees the publication of the new BNF 72 and the BNF for Children 2016-2017.
Previous eNewsletters can be found below:
A fault on the BNF and BNFC apps has been detected affecting some Apple iOS devices. A small amount of content may be out of date. Please delete the apps and reinstall them from the App store. Android devices and all online web versions of the BNF are unaffected.
There’s more to the BNF than you may think. Our BNF infographic shows the content and reach of the BNF.
Ceftriaxone has undergone substantial changes which are live in digital versions and will appear in print in BNF for Children 2016-2017 and BNF 72. These changes reflect the updated Summary of Product Characteristics (SPC) for Rocephin® and also advice and feedback from expert opinion and the BNF formulary committees.
Indication and dose
Indications and doses have been separated out. The umbrella term of “Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria” has been removed in preference of individual indications and dosing depending on the indications.
Children 1 month-11 years on mg/kg dosing can get a higher dose than children from 12 years on standard dosing
Doses for the European Summary of Product Characteristics were amended following consultation with the European Medicines Agency. In adults and children over 12 years of age, the recommended dose varies between 1 g and 4 g once daily depending on the indication. In children below 12 years of age, the recommended dose depends on both the body-weight of the patient and the indication. The full details behind these changes are available here: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Rocephin_30/WC500160112.pdf
Why has the age range Child 9–11 years (body-weight 50 kg and above) been chosen?
The SPC for Rocephin® states that a child 1 month–12 years with a body-weight over 50 kg should be dosed as for those of 12 years and above. However, the majority of children under 12 years will not weigh over 50 kg, therefore expert advice was taken to determine an appropriate age range of those under 12 years who may weigh above 50 kg. The age range of “Child 9–11 years (body-weight 50 kg and above)” was considered appropriate.
Route and Directions for Administration
The routes of administration have been split out to encourage the use of intravenous infusion as a first choice over other routes. It is important to read the Directions for Administration section before prescribing, clinically checking or administering ceftriaxone by a certain route.
The SPC for Rocephin® states that intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion only; in the light of this, the ceftriaxone monograph does not give the option of administration by intravenous injection in children 1 month–11 years and body-weight up to 50 kg. Where doses via intravenous infusion are not possible, doses can be given by deep intramuscular injection in the manner described under Directions for Administration.
As patients aged 9–11 years (body-weight 50 kg and above) may rarely receive doses less than 50 mg/kg, the option to administer the dose by intravenous injection is retained.
All children, excluding neonates, can receive ceftriaxone by deep intramuscular injection. The Directions for Administration should be followed when administering deep intramuscular injection in children.